The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens